Inhibition of Amyloid Precursor Protein Processing Enhances Gemcitabine-mediated Cytotoxicity in Pancreatic Cancer Cells *
Journal of Biological Chemistry, ISSN: 0021-9258, Vol: 288, Issue: 42, Page: 30114-30124
2013
- 31Citations
- 42Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations31
- Citation Indexes31
- 31
- CrossRef20
- Captures42
- Readers42
- 42
Article Description
Pancreatic adenocarcinoma or pancreatic cancer is often diagnosed at a very late stage at which point treatment options are minimal. Current chemotherapeutic interventions prolong survival marginally, thereby emphasizing the acute need for better treatment options to effectively manage this disease. Studies from different laboratories have shown that the Alzheimer disease-associated amyloid precursor protein (APP) is overexpressed in various cancers but its significance is not known. Here we sought to determine the role of APP in pancreatic cancer cell survival and proliferation. Our results show that pancreatic cancer cells secrete high levels of sAPPα, the α-secretase cleaved ectodomain fragment of APP, as compared with normal non-cancerous cells. Treatment of cells with batimastat or GI254023X, inhibitors of the α-secretase ADAM10, prevented sAPPα generation and reduced cell survival. Additionally, inhibition of sAPPα significantly reduced anchorage independent growth of the cancer cells. The effect of batimastat on cell survival and colony formation was enhanced when sAPPα downregulation was combined with gemcitabine treatment. Moreover, treatment of batimastat-treated cells with recombinant sAPPα reversed the inhibitory effect of the drug thereby indicating that sAPPα can indeed induce proliferation of cancer cells. Down-regulation of APP and ADAM10 brought about similar results, as did batimastat treatment, thereby confirming that APP processing is important for growth and proliferation of these cells. These results suggest that inhibition of sAPPα generation might enhance the effectiveness of the existing chemotherapeutic regimen for a better outcome. Background: Amyloid precursor protein (APP) and ADAM10, main α-secretase involved in generation of secreted APP (sAPPα), are overexpressed in pancreatic cancer. Results: Inhibition of APP processing by ADAM10 prevents anchorage independent growth and survival of cancer cells. Conclusion: Inhibition of sAPPα generation enhances chemotherapeutic potential of gemcitabine. Significance: Supplementing established pancreatic cancer therapy regimen with sAPPα inhibition will significantly improve the efficacy of treatment.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0021925820856889; http://dx.doi.org/10.1074/jbc.m113.459255; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84886938358&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/24022491; https://linkinghub.elsevier.com/retrieve/pii/S0021925820856889; http://www.jbc.org/lookup/doi/10.1074/jbc.M113.459255; https://syndication.highwire.org/content/doi/10.1074/jbc.M113.459255; https://dx.doi.org/10.1074/jbc.m113.459255
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know